Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro

Cancer Letters

Volumn 264, Issue 1, 2008, Pages 21-28

  Deubzer, Hedwig E ^a,b   Ehemann, Volker ^b   Kulozik, Andreas E ^b   Westermann, Frank ^a   Savelyeva, Larissa ^a   Kopp Schneider, Annette ^a   Riester, Daniel ^c   Schwab, Manfred ^a   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute for Microbiology and Genetics   (Germany)

Author keywords

E2F 1; HC toxin; N myc; RB tumor suppressor network; Retinoids

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; MYCOTOXIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN C MYB; PROTEIN MAD2; RETINOBLASTOMA PROTEIN; RETINOID; S PHASE KINASE ASSOCIATED PROTEIN 2; SURVIVIN; TRANSCRIPTION FACTOR E2F1; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; FLOW CYTOMETRY; HELMINTHOSPORIUM CARBONUM; HUMAN; HUMAN CELL; HYPHOMYCETES; IC 50; MICROSCOPY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HELMINTHOSPORIUM; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; MYCOTOXINS; NEUROBLASTOMA; PEPTIDES, CYCLIC; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

HELMINTHOSPORIUM CARBONUM;

EID: 42649106134     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.002     Document Type: Article

References (32)

1. Schwab M., Westermann F., Hero B., and Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4 (2003) 472-480
2. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., and Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid, Children's Cancer Group. N. Engl. J. Med. 341 (1999) 1165-1173
3. Gatta G., Capocaccia R., Stiller C., Kaatsch P., Berrino F., and Terenziani M. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J. Clin. Oncol. 23 (2005) 3742-3751
4. H.E. Deubzer, V. Ehemann, F. Westermann, R. Heinrich, G. Mechtersheimer, A.E. Kulozik, M. Schwab, O. Witt, Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells, Int. J. Cancer (2007) Epub ahead of print.
5. Hernando E., Nahle Z., Juan G., Diaz-Rodriguez E., Alaminos M., Hemann M., Michel L., Mittal V., Gerald W., Benezra R., Lowe S.W., and Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430 (2004) 797-802
6. Ito R., Asami S., Motohashi S., Ootsuka S., Yamaguchi Y., Chin M., Shichino H., Yoshida Y., Nemoto N., Mugishima H., and Suzuki T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol. Pharm. Bull. 28 (2005) 565-568
7. Miller M.A., Ohashi K., Zhu X., McGrady P., London W.B., Hogarty M., and Sandler A.D. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J. Pediatr. Hematol. Oncol. 28 (2006) 412-417
8. Oberthuer A., Warnat P., Kahlert Y., Westermann F., Spitz R., Brors B., Hero B., Eils R., Schwab M., Berthold F., and Fischer M. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett. 250 (2007) 250-267
9. Westermann F., Henrich K.O., Wei J.S., Lutz W., Fischer M., Koenig R., Wiedemeyer R., Ehemann V., Brors B., Ernestus K., Leuschner I., Benner A., et al. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin. Cancer Res. 13 (2007) 4695-4703
10. Reynolds C.P., Matthay K.K., Villablanca J.G., and Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 197 (2003) 185-192
11. Cinatl Jr. J., Cinatl J., Scholz M., Driever P.H., Henrich D., Kabickova H., Vogel J.U., Doerr H.W., and Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7 (1996) 766-773
12. Cinatl Jr. J., Cinatl J., Driever P.H., Kotchetkov R., Pouckova P., Kornhuber B., and Schwabe D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8 (1997) 958-963
13. Goettlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo. J. 20 (2001) 6969-6978
14. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., and Thiele C.J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62 (2002) 6108-6115
15. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
16. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug. Discov. 5 (2006) 37-50
17. Furchert S.E., Lanvers-Kaminsky C., Juurgen H., Jung M., Loidl A., and Fruhwald M.C. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int. J. Cancer 120 (2007) 1787-1794
18. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discov. 5 (2006) 769-784
19. Motegi A., Fujimoto J., Kotani M., Sakuraba H., and Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 17 (2004) 3319-3329
20. Fulda S., Honer M., Menke-Moellers I., and Berthold R. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur. J. Cancer 31A (1995) 616-621
21. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
22. Hildmann C., Wegener D., Riester D., Hempel R., Schober A., Merana J., Giurato L., Guccione S., Nielsen T.K., Ficner R., and Schwienhorst A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 124 (2006) 258-270
23. Witt O., Schweigerer L., Driever P.H., Wolff J., and Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr. Blood Cancer 43 (2004) 181
24. Brosch G., Ransom R., Lechner T., Walton J.D., and Loidl P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 7 (1995) 1941-1950
25. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., and Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98 (2001) 87-92
26. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, et al., Determination of the class and isoform selectivity of small molecule HDAC inhibitors, Biochem. J. (2007) Epub ahead of print.
27. Liu T., Tee A.E., Porro A., Smith S.A., Dwarte T., Liu P.Y., Iraci N., Sekyere E., Haber M., Norris M.D., Diolaiti D., Della Valle G., et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc. Natl. Acad. Sci. USA 104 (2007) 18682-18687
28. Keshelava N., Davicioni E., Wan Z., Ji L., Sposto R., Triche T.J., and Reynolds C.P. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J. Natl. Cancer Inst. 99 (2007) 1107-1119
29. Chen L., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001) 1653-1657
30. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 190 (1997) 595-606
31. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., and Kouzarides T. Regulation of E2F1 activity by acetylation. Embo. J. 19 (2000) 662-671
32. Walton J.D. HC-toxin. Phytochemistry 67 (2006) 1406-1413